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Cryptorchidism represents the most common endocrine disease in boys, with infertility
more frequently observed in bilateral forms. It is also known that undescended testes,
if untreated, lead to an increased risk of testicular tumors, usually seminomas, arising
from mutant germ cells. In normal testes, germ cell development is an active process
starting in the first months of life when the neonatal gonocytes transform into adult dark
(AD) spermatogonia. These cells are now thought to be the stem cells useful to support
spermatogenesis. Several researches suggest that AD spermatogonia form between 3 and
9 months of age. Not all the neonatal gonocytes transform into AD spermatogonia; indeed,
the residual gonocytes undergo involution by apoptosis. In the undescended testes, these
transformations are inhibited leading to a deficient pool of stem cells for post pubertal sper-
matogenesis. Early surgical intervention in infancy may allow the normal development of
stem cells for spermatogenesis. Moreover, it is very interesting to note that intra-tubular car-
cinoma in situ in the second and third decades have enzymatic markers similar to neonatal
gonocytes suggesting that these cells fail transformation into AD spermatogonia and likely
generate testicular cancer (TC) in cryptorchid men. Orchidopexy between 6 and 12 months
of age is recommended to maximize the future fertility potential and decrease the TC risk
in adulthood.
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INTRODUCTION
Undescended testis or cryptorchidism is the most common gen-
ital abnormality in boys. The prevalence of cryptorchidism in
full-term newborns range between 1 and 3%, reaching 30% in
prematures (1–3). The pathology is bilateral in about 20% of the
cases. About 80% of undescended testes are palpable and 20%
are non-palpable (3–5). Palpable undescended testes are located
along the inguino-scrotal region. Non-palpable testes may fall into
one of the following categories: intra-abdominal location, agene-
sis, intrauterine demise, or inguinal location caused by dysplasia
or atrophy. It is important to differentiate the true cryptorchidism
from the retractile testis, which is a normal finding and usually
it does not require surgical treatment. Acquired cryptorchidism
has been observed when the retractile testis ascent in the inguinal
canal during the infancy (ascending testis).
The main risk factors for the cryptorchid testis are infertility
and testicular cancer (TC).
The risk of infertility in adulthood is more significant in
patients with bilateral undescended testes (6). Approximately
10% of the infertile men have a history of cryptorchidism and
orchidopexy (7). Azoospermia is evident in 13% of unilateral
cryptorchidism and increase to 89% in untreated bilateral cryp-
torchid patients (8), although boys with one undescended testis
have a lower fertility rate, they have the same paternity rate as
boys with bilateral descended testes. Boys with bilateral unde-
scended testes have a lower fertility and a paternity rate (9). In
some studies, patients with unilateral cryptorchidism had normal
spermatogenesis, suggesting that additive detrimental factors may
be responsible for impaired fertility. The studied mechanisms
of the infertility in cryptorchidism are multiple (7). The hyper-
thermia, between 35 and 37°C rather than 33°C, evoked by the
abnormal position of the testis may respond for the impaired
spermatogenesis. Anatomical congenital anomalies associated to
undescended testis as testis–epididymis disjunction or iatrogenic
lesions of vas and testis during orchidopexy may also contribute to
infertility. Retrospective studies in infertile patients with history
of cryptorchidism have demonstrated an increased incidence of
anti-sperm antibodies which is more evident in pubertal age (1,
8). Sinisi et al. showed that cryptorchidism may elicit an autoim-
mune response against sperm antigens in childhood independent
of testis location and orchidopexy (1).
It is known that undescended testes, if untreated, lead to an
increased risk of TC, usually seminomas (10), arising from mutant
germ cells. TC is a solid neoplasm that has an incidence of 1% of all
cancers in men and is the most common between 20 and 30 years
of life (11, 12). Boys with an undescended testis have a 20-fold
higher risk to develop a TC and about 10% of the cases of TC
develop in men with a history of cryptorchidism (13).
In this review, we focus on the current knowledge about the
abnormal germ cell development in the undescended testes and
its possible relationship with the impaired spermatogenesis and
TC in adulthood. In the second section of this review, we discuss
the treatment of cryptorchidism and the possible role of the early
orchidopexy in the prevention of both infertility and cancer.
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GERM CELL DEVELOPMENT, INFERTILITY, AND TESTICULAR
CANCER IN CRYPTORCHIDISM
The germ cell development and its modification in cryptorchidism
have been recently matter of many researches (2, 14, 15).
Spermatogenesis is the process by which sperm cells are pro-
duced. In men, it starts at puberty, resulting from the increased
levels of gonadotropins and testosterone. It is a complex process
including sequential steps of mitosis, meiosis, and differentiation.
In each of these steps, endocrine, paracrine, and autocrine factors
are involved (16). Spermatogenesis takes place in the seminifer-
ous tubule: here germ cells are organized from the base of the
tubule to the lumen and progressively develop from spermatogo-
nia to spermatids. In the last step, spermatids differentiate through
morphological transformation into spermatozoa (spermiogene-
sis) (17) which are finally released from the Sertoli cells into the
lumen of the seminiferous tubule (spermiation).
However, germ cell development is an active process. It starts
during the first years after birth when neonatal gonocytes change
into adult dark (AD) spermatogonia. These are stem cells and
have a dark nucleus that specifically characterize them from the
other germ cells. Therefore, AD spermatogonia do not directly
take part to sperm production; nevertheless, they ensure a sup-
ply of stem cells for spermatogenesis. Indeed, AD spermatogonia
replicate to produce adult pale (AP) spermatogonia, with light
nuclei. These cells produce by mitosis the type B spermatogonia
which further divide and differentiate into primary spermato-
cytes which are already evident in the testes of children 4 years of
age (2, 18). Two sequential meiotic divisions and spermiogenesis
lead to final development of round spermatids and spermatozoa,
respectively (19).
Several data suggest that AD spermatogonia form between 3
and 9 months of age. This developmental cycle needs normal tes-
ticular hormones and the optimal scrotal temperature of 33°C
(20, 21). The hormonal regulation of these changes is not fully
understood, with evidence for a possible role of gonadotropins
and androgens. Not all the neonatal gonocytes transform into
AD spermatogonia. The remaining gonocytes undergo involution
by apoptosis. Genetic aberrations and environmental conditions
influence these processes.
The failure of transformation of gonocytes into AD spermato-
gonia may produce infertility in boys.
Hadziselimovic and Herzog (15) have demonstrated that the
process of transformation of neonatal gonocytes into AD sper-
matogonia during the first year of life is crucial for male fertility.
The inhibition of this process in undescended testis leads to a
deficient pool of stem cells for post pubertal spermatogenesis and
infertility. Moreover, in undescended testes, germ cells loss starts
at 6 months of age. Testicular biopsies at time of orchidopexy
confirmed the importance of AD spermatogonia for fertility in
cryptorchid patients. Tasian and coworkers (22) observed greater
germ cell depletion in abdominal testes compared with palpable
testes and a progressive germ cell loss for each month the testes
remain undescended.
It is very interesting to note that the intra-tubular carcinoma
in situ (CIS) in the second and third decade has enzyme markers
similar to neonatal gonocytes as placental alkaline phosphatase
expression, suggesting that these cells, that fail to develop in AD
spermatogonia at 3–9 months of age, are the origin of cancer in
cryptorchid men (23). Studies have suggested that the precursor
cells of testis cancer, testicular CIS, are similar to fetal gonocytes. A
current hypothesis (2) is that,due to the high temperature anomaly
of undescended testis, an abnormal apoptosis allows some gono-
cytes to persist and become CIS with progressive mutation and/or
cellular unbalance, and eventually malignancy in adulthood. These
abnormal gonocytes are kept in a defined environment“suspended
animation”in the germ-line and, due to the accumulation of muta-
tions,may undergo transformation becoming the source of the CIS
(2, 21, 24).
The etiology accepted for germ cell carcinoma remains
unknown, although disturbances in the microenvironment pro-
vided by the Sertoli and Leydig cells may play an important
role. In fact, spermatogenesis is strictly controlled and depends
on a succession of signals supplied from the local environment
(11, 25, 26) and Leydig cells, next to their steroidogenic func-
tion, during development express the insulin-like-3 gene (INSL3),
which is responsible for gubernaculum maturation and testicu-
lar descent (27). A specific association of mutations in INSL3
with cryptorchidism has been described but its possible role in
TC development and infertility needs to be clarified (28).
Olesen et al. linked the development of TC not only with
cryptorchidism but also with other urogenital anomalies such as
hypospadia (29). In fact, epidemiological studies in males who
presented fertility problems tend to lean toward an enhanced risk
of testicular germ cell tumor (30). The development of TC is asso-
ciated with many chromosomal abnormalities and this raises the
problem for close monitoring of these patients. Kanetsky et al.
(31) demonstrated common genetic variants associated to an
increased risk of testicular germ cell cancer (TGCC) and found
that seven markers at 12p22 within KITLG (c-KIT ligand) reached
genome-wide significance. This gene has been involved in sev-
eral aspects of primordial germ cell development, migration, and
survival (32).
Concerning the development of the urogenital sinus and par-
ticularly the testis, the impacts of endocrine disruptors have been
fairly well described on human and experimental models (33–35).
This is especially true for hypospadia, cryptorchidism, and infertil-
ity; but the link with TGCC has to be explained. The unbalanced
equilibrium between the estrogen and androgen levels in utero
is hypothesized to influence the risk of TC. Thus, mutations in
testosterone gene expression may change the level of testosterone
in vivo and hypothetically the risk of developing TC (36).
As discussed before, hormonal regulation is very significant
in the development of the germ-line. Beside the importance of
fetal development, it seems that puberty should be an important
moment, when hormone levels reach optimal concentrations for
the secondary sex characters development. It has been shown that
sperm agglutinating antibodies appear in young boys with cryp-
torchidism and they are more prevalent during puberty (1). This
also coincides with the appearance of TGCC, as men affected are
between 15 and 35 years old, suggesting that puberty and prob-
ably the increase in hormone concentrations should be central
issues (37).
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HORMONAL AND SURGICAL TREATMENT OF
CRYPTORCHIDISM
The goals of treatment of cryptorchidism are mainly two: preserve
fertility and reduce the risk of neoplastic disease. Last but not the
least, treatment allows the testicular self-examination for an early
diagnosis and detection of TC.
Hormonal treatment with human chorionic gonadotropin
(hCG) or gonadotropin-releasing hormone (GnRH) may be ini-
tially administered for cryptorchidism because it should promote
the testicular descent (38). The theoretical basis for its use is
to stimulate the Leydig cells to produce testosterone, inducing
inguinal–scrotal testicular descent. Potential harmful effects of
hormonal treatment on the developing testes, including apop-
tosis, inflammation, and reduced number of germ cells are still
under study. In addition, there are reports which suggest that the
hormonal stimulation in infancy may be damaging to the testes
(39). It has been observed, in hCG-treated rats, a poor differ-
entiation of the seminiferous epithelium, with high Leydig cell
evidence and increased inter-tubular eosinophilic material (40).
These experimental data emphasize the possible negative outcome
of hormone therapy on germ cell line and its main action on Leydig
cells. The increased synthesis of vascular endothelial growth factor
(VEGF), determined by hCG therapy also highlights the increased
cell permeability causing interstitial edema. The role of VEGF on
spermatogenesis is unclear. Several findings have revealed several
inhibitory effects of VEGF on spermatogenesis (40, 41).
Considering the poor efficacy and the possible adverse effects
of hormonal therapy, surgery must be preferred (42).
Orchidopexy is the cornerstone of cryptorchidism treatment.
Inguinal operation is the standard approach for palpable testis.
Laparoscopy is the gold standard technique for both diagnosis
and treatment of non-palpable testes (3–5). Early surgical treat-
ment may preserve fertility. Orchidopexy is commonly performed
before 2 years of age and increasing research suggest that surgery
before 1 year of age may permit the normal spermatogenesis by
preventing degenerative changes of the testes and germ cell loss
(22, 43). However, early orchidopexy does not guarantee normal
fertility in adulthood. Hadziselimovic showed that despite orchi-
dopexy before 6 months of age, up to 35% of boys will grow up
to be infertile regardless of the normal total germ cell count on
testicular biopsies performed at the time of orchidopexy (44). The
current practice for the acquired cryptorchidism is to operate at
diagnosis, by a scrotal approach, although the prognosis seems to
be better than congenital cryptorchidism considering the normal
development and apoptosis of the germinal cells during the first
year of life.
Since the link between cryptorchidism and TC seems to be
an abnormal development of the primary germ-line, any attempt
to normalize this process, as early surgery, will permit a nor-
mal growth of germ cells, thereby avoiding cancer as well as
oligospermia or azoospermia. However, it should be mentioned
that some studies failed to demonstrate a correlation between
the time of surgery and cancer risk (45). A systematic review
and meta-analysis of the literature by an American group has
concluded that prepubertal orchiopexy may decrease the risk of
malignancy and that early surgical intervention is indicated in
children with cryptorchidism leading to a better growth of the
testis (46).
CONCLUSION
Cryptorchidism is a risk factor for infertility and TC in adulthood.
To date, orchidopexy is recommended between 6 and 12 months
of age. The aim of an early surgical intervention is to prevent the
abnormal germ cell development and ultimately decrease the risk
of infertility and malignancy in adulthood.
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